Obstetrics/Gynecology
RSSArticles
-
New patch options — Could they catch on?
When the Ortho Evra transdermal contraceptive (Ortho Women's Health & Urology, Raritan, NJ) was introduced in 2002, use of the patch caught on quickly with young women. -
Contraceptive Technology Update May 2011 Issue in PDF
-
OB/GYN Quarterly Update: Heavy menstrual bleeds given new treatment
Recent investigation into the molecular pathogenesis of epithelial ovarian cancer has implicated two dominant phenotypes. -
OB/GYN Quarterly Update: Heavy menstrual bleeds given new treatment
After two pretreatment cycles, 196 patients with menorrhagia were randomized to tranexamic acid or placebo. -
Research eyes chlamydia, ectopic pregnancy link
A ruptured ectopic pregnancy is the leading cause of maternal mortality in the first trimester and accounts for 10 to 15% of all maternal deaths. -
Do more pill packs mean fewer pregnancies?
What is your facility's policy on providing multiple pill packs? Results of a new study might make you rethink your strategy. -
Female condoms hit the spotlight — Will U.S. women see more options?
Since its introduction in 2009, use of the non-latex FC2 Female Condom (Women's Health Co., Chicago) has grown. -
Clinical Briefs by Louis Kuritzky, MD
In animal models, aspirin (asa) has favorable effects on the incidence and/or growth rate of some cancers (CA). -
Ceftaroline Fosamil Injection (Teflaro™)
A broad-spectrum, parenteral, cephalosporin with activity against both gram-positive and gram-negative bacteria has been approved by the FDA. Ceftaroline fosamil is the prodrug of ceftaroline and is marketed by Forest Pharmaceuticals as Teflaro™. -
Internal Medicine Alert - Full March 29, 2011 Issue in PDF